[Federal Register Volume 68, Number 39 (Thursday, February 27, 2003)]
[Notices]
[Pages 9091-9092]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-4567]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 01E-0367]
Determination of Regulatory Review Period for Purposes of Patent
Extension; Starlix
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) has determined the
regulatory review period for Starlix and is publishing this notice of
that determination as required by law. FDA has made the determination
because of the submission of an application to the Director of Patents
and Trademarks, Department of Commerce, for the extension of a patent
that claims that human drug product.
ADDRESSES: Submit written comments and petitions to the Dockets
Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to
http://www.fda.gov/dockets/ecomments.
FOR FURTHER INFORMATION CONTACT: Claudia Grillo, Office of Regulatory
Policy (HFD-013), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-3460.
SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug
and Patent Term Restoration Act (Public Law 100-670) generally provide
that a patent may be extended for a period of up to 5 years so long as
the patented item (human drug product, animal drug product, medical
device, food additive, or color additive) was subject to regulatory
review by FDA before the item was marketed. Under these acts, a
product's regulatory review period forms the basis for determining the
amount of extension an applicant may receive.
A regulatory review period consists of two periods of time: a
testing phase and an approval phase. For human drug products, the
testing phase begins when the exemption to permit the clinical
investigations of the drug becomes effective and runs until the
approval phase begins. The approval phase starts with the initial
submission of an application to market the human drug product and
continues until FDA grants permission to market the drug product.
Although only a portion of a regulatory review period may count toward
the actual amount of extension that the Director of Patents and
Trademarks may award (for example, half the testing phase must be
subtracted, as well as any time that may have occurred before the
patent was issued), FDA's determination of the length of a regulatory
review period for a human drug product will include all of the testing
phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).
FDA recently approved for marketing the human drug product Starlix
(nateglinide). Starlix is indicated as monotherapy to lower blood
glucose in patients with Type 2 diabetes (non-insulin dependent
diabetes mellitus, NIDDM) whose hyperglycemia cannot be adequately
controlled by diet and physical exercise and who have not been
chronically treated with other anti-diabetic agents. Subsequent to this
approval, the Patent and Trademark Office received a patent term
restoration application for Starlix (U.S. Patent No. 34,878) from
Novartis, and the Patent and Trademark Office requested FDA's
assistance in determining this patent's eligibility for patent term
restoration. In a letter dated October 2, 2001, FDA advised the Patent
and Trademark Office that this human drug product had undergone a
regulatory review period and that the approval of Starlix represented
the first permitted commercial marketing or use of the product. Shortly
thereafter, the Patent and Trademark Office requested that FDA
determine the product's regulatory review period.
FDA has determined that the applicable regulatory review period for
Starlix is 2,147 days. Of this time, 1,775 days occurred during the
testing phase of the regulatory review period, while 372 days occurred
during the approval phase. These periods of time were derived from the
following dates:
1. The date an exemption under section 505 of the Federal Food,
Drug, and Cosmetic Act (the act) (21 U.S.C. 355) became effective:
March 9, 1995. The applicant claims February 7, 1995, as the date the
investigational new drug application (IND) became effective. However,
FDA records indicate that the IND became effective on March 9, 1995,
which is 30 days after FDA's receipt of the IND.
2. The date the application was initially submitted with respect to
the human drug product under section 505 of the act: December 17, 1999.
FDA has verified the applicant's claim that the new drug application
(NDA) for Starlix (NDA 21-204) was initially submitted on December 17,
1999.
3. The date the application was approved: December 22, 2000. FDA
has verified the applicant's claim that NDA 21-204 was approved on
December 22, 2000.
This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the U.S.
Patent and Trademark Office applies several statutory limitations in
its calculations of the actual period for patent extension. In its
application for patent extension, this applicant seeks 1,259 days of
patent term extension.
Anyone with knowledge that any of the dates as published are
incorrect may submit to the Dockets Management (see ADDRESSES) written
comments and ask for a redetermination by April 28, 2003. Furthermore,
any interested person may petition FDA for a determination regarding
whether the applicant for extension acted with due diligence during the
regulatory review period by August 26, 2003. To meet its burden, the
petition must contain sufficient facts to merit an FDA investigation.
(See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41-42, 1984.)
Petitions should be in the format specified in 21 CFR 10.30.
Comments and petitions should be submitted to the Dockets
Management Branch. Three copies of any information are to be submitted,
except that individuals may submit a single copy. Copies are to be
identified with the docket number found in brackets in the heading of
this document. Comments and petitions may be seen in the
[[Page 9092]]
Dockets Management Branch between 9 a.m. and 4 p.m., Monday through
Friday.
Dated: January 13, 2003.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug Evaluation and Research.
[FR Doc. 03-4567 Filed 2-26-03; 8:45 am]
BILLING CODE 4160-01-S